作者: Anna Ramunno , Sandro Cosconati , Stefania Sartini , Vita Maglio , Sara Angiuoli
DOI: 10.1016/J.EJMECH.2012.02.045
关键词: Receptor 、 Inflammation 、 Pharmacology 、 Aldose reductase 、 Metastasis 、 Docking (molecular) 、 Chemistry 、 Endocrinology 、 Internal medicine 、 Diabetes mellitus 、 Fidarestat 、 Diabetic neuropathy
摘要: Aldose reductase (ALR2) is a crucial enzyme in the development of major complications diabetes mellitus. Very recently it has been demonstrated that ARL2 inhibitor, fidarestat, significantly prevents inflammatory signals (TNF-α, LPS) cause cancer (colon, breast, prostate and lung), metastasis, asthma, other diseases. Currently, fidarestat phase III clinical trial for diabetic neuropathy was found to be safe. Thus finding novel, potent inhibitors today more than past great demand as they can pave way novel therapeutic approach number diseases besides diabetes. Herein, starting from virtual screening-derived ALR2 inhibitor S12728 (1), rational receptor-based lead optimization undertaken. The design synthetic efforts here reported led discovery several new compounds endowed with low micromolar/submicromolar activities.